Pharmafile Logo
Pharmafocus logo
Advanced Search

epilepsy

Showing 15 posts of 46 posts found.

UCB sponsors ‘Hack Epilepsy’ digital event

March 12, 2015
Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat

Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …

News
UCB image

UCB epilepsy drug reaches regulatory bodies

January 21, 2015
Research and Development, Sales and Marketing EMA, FDA, UCB, brivaracetam, epilepsy

UCB has established regulatory milestones for its investigational antiepileptic drug brivaracetam in Europe and the US. The Food and Drug …

News
Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

News
Eisai image

SMC first to give Fycompa thumbs-up

December 12, 2012
Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy

The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …

News
Eisai image

Eisai launches epilepsy drug in UK

September 14, 2012
Sales and Marketing Eisai, UK, epilepsy

Eisai has launched its first-in-class epilepsy drug Fycompa in the UK, prior to a roll-out in EU member states including …

News

Eisai to enter Russia with epilepsy launch

June 27, 2012
Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy

Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …

News

Recommendations for two Eisai epilepsy drugs

May 28, 2012
Sales and Marketing CHMP, Eisai, Zonegra, epilepsy

European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …

News

UCB signs new epilepsy research pact with Imperial

May 21, 2012
Research and Development, Sales and Marketing R&D, Scotland, UCB, epilepsy

UCB has signed a two-year research deal with Imperial College London to find disease-modifying targets in epilepsy. The firm has …

News
UCB image

UCB releases ‘Epilepsy In Our Time’ video diaries

February 17, 2012
Medical Communications UCB, epilepsy

UCB has released Epilepsy In Our Time, a video diary that explores life with epilepsy from the perspective of those …

News

Zonegran study could pave way for paediatric licence

September 2, 2011
Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news

Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …

News
FDA building

FDA refuses to file Eisai’s epilepsy drug

August 1, 2011
Sales and Marketing Eisai, FDA, epilepsy

The FDA has refused to file Eisai’s epilepsy drug perampanel, saying it needs more information for the treatment. The FDA …

News
GlaxoSmithKline

GSK’s epilepsy treatment Potiga wins US approval

June 13, 2011
Sales and Marketing GSK, Potiga, Trobalt, Valeant, epilepsy

The FDA has approved GlaxoSmithKline and Valeant’s epilepsy treatment Potiga, but the drug will require further review before it can …

News

GSK’s Trobalt launched in UK

May 25, 2011
Sales and Marketing GlaxoSmithKline, Trobalt, epilepsy, retigabine

GSK has launched its new epilepsy treatment Trobalt in the UK. Trobalt (retigabine) is as adjunctive treatment of partial onset …

News

GSK and Valeant’s epilepsy treatment approved

April 8, 2011
Sales and Marketing GSK, Trobalt, Valeant, epilepsy

The European Commission has granted marketing authorisation for Trobalt, the new epilepsy drug from GSK and Valeant. Trobalt (retigabine) has …

News

Encouraging data for Eisai epilepsy drug

August 24, 2010
Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306

A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023